FIELD: pharmacology.
SUBSTANCE: document describes methods of using compounds of formula (I) to modulate PKM2 activity in a subject. The invention relates to the field of pharmacology and medicine and is aimed at modulating the activity of M2-pyruvate kinase (PKM2). The use of a compound selected from the group or a pharmaceutically acceptable salt of any of the above compounds for the treatment of diseases associated with abnormal PKM2 activity is disclosed, the disease being selected from the group consisting of cancer, obesity, diabetes-related disease, atherosclerosis, coronary artery disease (CAD), Bloom's syndrome (BS), or an autoimmune disease.
EFFECT: invention provides effective treatment of diseases associated with PKM2 activity.
20 cl, 14 dwg, 29 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICINAL COMPOUNDS | 2014 |
|
RU2691105C1 |
| NITROIMIDAZOLE DERIVATIVE AGAINST PULMONARY TUBERCULOSIS | 2016 |
|
RU2675622C1 |
| AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | 2019 |
|
RU2801140C2 |
| INHIBITORS OF CDK | 2011 |
|
RU2621674C2 |
| HETEROCYCLIC COMPOUNDS AND METHODS OF APPLICATION | 2009 |
|
RU2525116C2 |
| PROTEIN KINASE INHIBITORS FOR ENHANCING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | 2019 |
|
RU2822216C2 |
| MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS USING THEM AND WAYS OF USE THEREOF | 2020 |
|
RU2825271C2 |
| BICYCLIC DIHYDROPYRIMIDINECARBOXAMIDE DERIVATIVES AS RHO-KINASE INHIBITORS | 2017 |
|
RU2778478C2 |
| PYRAZOLO[1,5-A]PYRIMIDINYLCARBOXAMIDES AND THEIR USE FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS | 2017 |
|
RU2799332C2 |
| BROMDOMAIN INHIBITORS | 2012 |
|
RU2671571C1 |
